Global Automated And Rapid Microbiological Tests Market - ABC6 - Providence, RI and New Bedford, MA News, Weather

Global Automated And Rapid Microbiological Tests Market

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Reportlinker

NEW YORK, July 9, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

Global Automated And Rapid Microbiological Tests Market

 

http://www.reportlinker.com/p092467/Global-Automated-And-Rapid-Microbiological-Tests-Market.html

 

This report analyzes the worldwide markets for Automated And Rapid Microbiological Tests in US$ Thousands by the following End-Use Segments: Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, & Other Automated & Rapid Microbiological Tests), and Non-Clinical Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 103 companies including many key and niche players such as -

 

Abbott Laboratories

Alere Inc.

Becton Dickinson and Company

bioMerieux SA

Bio-Rad Laboratories, Inc.

 

 

 

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-2

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

Clinical Applications I-4

Automated Identification and Susceptibility Systems I-4

Automated Blood Culture Systems I-4

Automated Tuberculosis Systems I-4

Streptococcal Infection Rapid Tests I-4

GC/Chlamydia Rapid Tests I-5

Other Automated & Rapid Microbiological Tests I-5

Non-Clinical Applications I-5

 

 

II. EXECUTIVE SUMMARY

 

1. INDUSTRY OVERVIEW II-1

Global Invitro-Diagnostics Market II-1

Table 1: Global In Vitro Diagnostics (IVD) Market by

Geographic Region (2013): Percentage Share Breakdown of

Revenues for the United States, Europe, and Rest of World

(includes corresponding Graph/Chart) II-1

 

Table 2: Global In-Vitro Diagnostics Market by Sector (2013):

Percentage Breakdown of Revenues for Hospital & Commercial

Laboratories, Decentralized & Patient Self-Testing, (includes

corresponding Graph/Chart) II-2

 

Table 3: Global In-Vitro Diagnostics Market by Segment

(2013): Percentage Breakdown of Value Sales for Hematology,

Hemostasis, Immunochemistry, Microbiology, Molecular

Diagnostics, Point-of-Care Diagnostics, Self-Monitoring Blood

Glucose, and Tissue Diagnostics (includes corresponding

Graph/Chart) II-2

 

Table 4: Global In Vitro Diagnostics Market by Leading Player

(2013): Percentage Share Breakdown of Revenues for Abbott,

Biomerieux, Danaher, J&J, Roche, Siemens and Others (includes

corresponding Graph/Chart) II-3

Automated and Rapid Microbiological Tests Revolutionize

Microbiological Testing II-3

Evolutionary Battle against Microbes Drives Market Future II-4

Automated Microbiological Tests: A Pesky Gray Area in the

Clinical Diagnostics Market II-5

Instant Detection of Pathogens - A New Epoch in the Fight for

Survival II-5

Traditional Rapid Microbiological Tests Make Way for New,

Probe Tests II-6

Emerging Markets Provide Tremendous Growth Opportunities II-7

Clinical Applications II-8

Table 5: Global Automated and Rapid Microbiological Tests

Market in Clinical Applications by Region: (2014) (includes

corresponding Graph/Chart) II-8

 

Table 6: Global Automated and Rapid Microbiological Tests

Market in Clinical Applications by Segment: (2014) (includes

corresponding Graph/Chart) II-9

Non-Clinical Applications II-9

Table 7: Global Automated and Rapid Microbiological Tests

Market in Non-Clinical Applications by Region: (2014)

(includes corresponding Graph/Chart) II-10

A Holistic Peek into a Few Noteworthy Trends II-11

The Evolution of Biotechnology - A Crucial Step Ahead in the

Growing Popularity of Rapid Microbial Tests II-11

Point-of-Care Rapid Microbiological Testing: Yet to Realize

Its Full Potential II-12

 

2. COMPETITION II-14

Table 8: Global Microorganism Identification and Resistance

Tests Market by Leading Player (2013): Percentage Market Share

Breakdown of Value Sales for Becton Dickinson and Co,

BioMérieux, and Others (includes corresponding Graph/Chart) II-14

 

Table 9: Global Blood Screening Market by Leading Player

(2013): Percentage Market Share Breakdown of Value Sales for

Hologic Gen-Probe, Roche and Others (includes corresponding

Graph/Chart) II-14

 

Table 10: Global GC-CT Testing Market by Leading Player

(2013): Percentage Market Share Breakdown of Value Sales for

Becton Dickinson & Co, Hologic Gen- Probe, Qiagen NV, Roche

and Others (includes corresponding Graph/Chart) II-15

Competitive Dynamics in the C. Difficile Testing Market II-15

Table 11: Global Molecular Diagnostics Market for Clostridium

difficile by Leading Player (2013): Percentage Breakdown of

Revenues for Becton Dickinson, Cepheid, Meridian and Others

(includes corresponding Graph/Chart) II-15

 

Table 12: Global Immunoassays Market for Clostridium

difficile by Leading Player (2013): Percentage Breakdown of

Revenues for Meridian and Others (includes corresponding

Graph/Chart) II-16

A List of Select Molecular C. difficile Test Products II-16

 

3. MARKET DRIVERS AND TRENDS II-17

Increasing Incidence of Infectious Diseases - An Opportunity

Indicator II-17

Table 13: Reported Cases of Major Infections by Select

Geographic Region: 2011 II-17

Rising Healthcare Needs of Aging Global Population - A Growth

Driver II-18

Table 14: Global Population Statistics for the 65+ Age Group

(2012) (includes corresponding Graph/Chart) II-19

 

Table 15: Elderly Population (65+ Years) as a % of Total

Population (2025) (includes corresponding Graph/Chart) II-20

Rising HIV Prevalance - A Key Opportunity Indicator II-20

Some Significant HIV Statistics by Region: 2011 II-21

Table 16: Global Prevalence of HIV Infection in 2012 by

Region (in Millions) (includes corresponding Graph/Chart) II-22

 

Table 17: Newly Infected HIV Population in 2012 by Region

(in Millions) (includes corresponding Graph/Chart) II-23

 

Table 18: Global HIV Related Deaths in 2012 by Region (in

Millions) (includes corresponding Graph/Chart) II-24

 

Table 19: Top Twelve Countries in Apac with The Highest Hiv

Incidence (2012) (includes corresponding Graph/Chart) II-25

 

Table 20: Global HIV Prevalence among Adults and Youth in

2010 (includes corresponding Graph/Chart) II-26

Rapid HIV Tests: A New Age Diagnostic Weapon against the

Killer Disease II-26

Ultra-Rapid HIV-Screening Tests put up a Strong Fight against

HIV-Epidemic II-27

Accuracy/Reliability of Home HIV Testing: A Bone of Contention II-27

Increase in Healthcare Spending in Emerging Markets to Propel

Demand II-28

Table 21: Healthcare Spending as % of GDP in Select Countries

(2011) (includes corresponding Graph/Chart) II-28

Rising Emphasis on Lab Automation to Augur Well for Market Growth II-29

Greater Patient Awareness to Drive Growth II-29

Advancements in Molecular Diagnostics - A Boon II-29

Antibiotic Resistant Bacteria Throws the Spotlight on

Microbial Testing II-30

Influenza - Boosting Rapid Test Prospects II-30

Select FDA-approved Rapid Detection Tests for Flu A&B: (2012) II-31

Automated Blood Culture Systems: The Gold Standard in the

Fight against Bacteremia II-32

Impact of Food Scares on Rapid Microbiological Tests Market II-33

Stringent Norms Necessitate Microbial Food Safety Testing II-34

Rapid Screening Gains Preference over Traditional Food Testing

Procedures II-34

Leading Food Processors Resort to Rapid Microbiological Testing II-35

Food Packages of the Future Ingrained with Microbial Alert

Systems II-36

Poultry Industry Embraces Rapid Microbiological Testing

Technologies II-36

Rapid Microbiological Tests Gain Significance in the Pharma

Industry II-36

Key Advantages of Rapid Microbiological Tests for Pharma- In

a Nutshell II-37

Growth Direct™ System Creates Waves in the Pharmaceutical

Quality Control II-38

 

4. KEY ISSUES CONFRONTING THE RAPID MICROBIOLOGICAL TESTS MARKET II-39

Validation: An Imperative Prerequisite II-39

Obtaining Regulatory Approval: A Major Non-Technical Hindrance II-39

Non-Conformance to Testing Requirements: A Weighty Concern II-39

Technical and Cost Issues Impede the Uptake of Rapid

Microbiological Tests in the Food Sector II-40

 

5. PRODUCT/TECHNOLOGY OVERVIEW II-41

Automated & Rapid Microbiological Tests: A Definition II-41

How Does a Rapid Test Work? II-41

Enabling Technologies of Automated & Rapid Microbiological Tests II-42

Growth-based Technologies II-42

Viability-based Technologies II-42

Cellular-Component or Artifact-based Technologies II-42

Genomics/Proteomics II-42

Microarrays/Microfluidics II-42

DNA Microchips/Probes II-43

Polymerase Chain Reaction (PCR) II-43

Immunoassay II-44

Nucleic Acid Testing (NAT) II-44

Nucleic Acid Probes II-45

Signal-Amplified Tests II-45

Nucleic Acid Amplification Tests II-45

Traditional Methods with Computer-Aided Imaging II-46

Combination Methods II-46

 

6. APPLICATION AREAS OF AUTOMATED AND RAPID MICROBIOLOGICAL

TESTS- A REVIEW II-47

Clinical Applications II-47

Automated Identification and Susceptibility Systems II-47

Automated Blood Culture Systems II-47

Automated Tuberculosis Systems II-47

Streptococcus Infection Rapid Tests II-47

Streptococcus A Rapid Tests II-48

Streptococcus B Rapid Tests II-48

GC/Chlamydia Rapid Tests II-49

Other Automated & Rapid Microbiological Tests II-49

Respiratory Rapid Tests II-49

RSV/ Influenza Rapid Tests II-50

Gastrointestinal Rapid Tests II-50

Giardia Lamblia Rapid Tests II-50

H. Pylori Rapid Tests II-50

Cryptosporidium Rapid Tests II-51

C. Difficile Rapid Tests II-51

STD Rapid Tests II-52

HIV Rapid Tests II-52

Advantages of Rapid HIV Testing II-53

Disadvantages of Rapid HIV Testing II-53

Syphilis Rapid Tests II-53

Applications in Non-Clinical Investigations II-54

Food/Water Safety Tests II-54

Food Safety Testing: A Lucrative Application Area II-54

qPCR Application in Food Microbiology: Study of Select

Micro-Organisms by Target Gene and Food Substrate II-55

Rapid Microbiological Methods in Pharmaceutical Sector II-56

Limitations II-57

Advantages II-57

Applications in Pharmaceutical Sector II-57

Environmental Tests II-58

Other Miscellaneous Applications II-58

 

7. PRODUCT INNOVATIONS/INTRODUCTIONS II-59

Neogen Rolls Out NeoFilmTM for Microbial Tests II-59

bioMérieux Unveils TEMPO® AC Automated Test II-59

Neogen Introduces New Soleris® Rapid Assays for Sterility Testing II-59

Pall Introduces GeneDisc II-60

Rapid Micro Biosystems to Launch Next-Generation Growth

DirectTM Systems II-60

Bruker Unveils Single-Use MALDI BiotargetTM Sample Plates II-60

Becton, Dickinson and Company Introduces BD BACTEC™ SafePod II-61

Applied Visual Sciences Introduces TBDxV™ TB Diagnostic Aid II-61

Neogen Introduces Faster Soleris® Test for Detecting Mold and

Yeast II-61

BioControl Systems Develops PCR for Detecting Non-O157

Serotypes of STEC II-62

InDevR Introduces New Virus Counter II-62

MicroPhage Receives Approval from FDA for KeyPath™ MRSA/MSSA

Blood Culture Test - BT II-62

Health Canada Approves DuPont's BAX® System Real-Time Assay II-63

Neogen Receives Approval from AOAC for Reveal 2.0 Test II-63

Life Technologies and University of Pennsylvania School of

Veterinary Medicine Introduce TaqMan® Salmonella enteritidis

Detection Kit II-63

AdvanDX Obtains 510(k) Clearance from US FDA for GNR Traffic

Light™ PNA FISH® II-63

Abbott Laboratories Introduces PLEX-ID™ Biothreat Assay II-63

bioMerieux Receives FDA Clearance for NucliSENS EasyQ MRSA II-64

BD Launches BD Max™ Open System II-64

Luxcel Biosciences and Mocon Develop GreenLight™900 Series II-64

Bruker Launches pTD™ for Homeland Security II-64

Hygiena International Launches EnSURE II-65

 

8. RECENT INDUSTRY ACTIVITY II-66

MedMira Secures Approval from COFEPRIS II-66

MedMira Secures Marketing Approval for Enriched Version of

Reveal® Rapid HIV Test (Europe) II-66

Corgenix Medical Announces Expansion of Viral Hemorrhagic

Fever Rapid Testing Facilities in Sierra Leone II-66

MedMira and National Research Council of Canada Ink

Collaborative Research Agreement II-67

CML HealthCare Installs BD Kiestra Total Laboratory Automation

System at Central Laboratory II-67

BioMérieux Obtains FDA Clearance for Vitek MS Clinical

Microbiology System II-67

Cepheid Obtains FDA Clearance for Xpert® MTB/RIF Test II-68

Rapid Micro Biosystems Receives Funding from Various Capital

Ventures to Support Growth DirectTM System II-68

Instant BioScan Rolls Out Real-Time Microbial System for Water II-68

Becton, Dickinson and Company Takes Over KIESTRA Lab Automation II-69

Duzen and Bruker Enter into Exclusive Framework Agreement II-69

Bruker Enters into Collaboration with Special Bacteriology

Reference Laboratory II-69

Terumo Completes Merger with CaridianBCT II-70

LabCorp to Develop a Novel Laboratory-based Antibiotic

Susceptibility Assay II-70

Nanosphere Receives FDA Authorization for Marketing BC-GP Test II-70

BD Diagnostics Introduces New Molecular Test II-71

BD Diagnostics Receives Approval for Plastic Blood Culture

Bottles II-71

Cepheid Develops Xpert CT/NG and Xpert CT Next-Generation

Molecular Products II-71

BIT Analytical Instruments and DRG Diagnostics Launch New

Product for Analyzing Immunoassays Parameters II-72

Verigene System Introduces Instrument for Automatic Bacterial

Identification in Blood Culture Test II-72

Block Scientific Supplies BACTECTM 9000 Range of Blood Culture

Systems II-72

Valio Signs Agreement with DSM II-73

CML HealthCare Inks Agreement with Becton, Dickinson and Company II-73

Abbott Secures CE Marking for PLEX-IDTM System and Clinical

Assays II-73

Abbott Laboratories and Genetics Laboratory to Enter into

Collaboration for Development of Molecular Diagnostic Test II-74

Bruker Extends Distribution Agreement with Francisco Soria

Melguizo II-74

Laboratory Viollier and Bruker Extend Existing Agreement II-74

Thermo Fisher Scientific Receives FDA Approval for Sensititre

OptiRead Automated Fluorometric Plate Reading System II-75

Magellan Biosciences Obtains FDA Approval for Sensititre AIM

Automated Inoculation Delivery System II-75

bioMérieux Receives FDA Approval for NucliSENS EasyQ® MRSA II-75

BD Diagnostics Obtains FDA Approval for BD ProbeTecTM Assays II-76

Signature Mapping Medical Sciences Receives Order from Aurum

Institute for Health Research II-76

Mindray Medical Takes Over Stake in Hunan Changsha Tiandiren

Biotech II-76

UL Acquires MDT and MDRS II-76

Thermo Fisher Scientific Takes over TREK Diagnostic Systems II-77

Eurofins Acquires Lancaster Laboratories II-77

Polyplus-Transfection Inks Agreement with ExcellGene for

Transfection Reagents II-77

Merck Acquires Microbiology Division of Biotest II-77

UL Establishes New Water Testing Laboratory in India II-78

Neogen Obtains FDA Clearance Reveal for Salmonella Enteritidis

(SE) Fast Test II-78

Sekisui Chemical Acquires Diagnostic Products Business of Genzyme II-78

Dynacare Laboratories Acquires Bruker MALDI Biotyper System II-79

Magellan Biosciences Enters into Partnership with miacom

Diagnostics II-79

Lonza Signs Distribution Agreement with Roche II-79

BD Enters into Collaboration with Bruker Daltonics II-79

Seegene Enters into Partnership with Molzym II-79

bioMérieux Enters into Partnership with Shanghai Institutes

for Biological Sciences II-80

Becton, Dickinson and Company Acquires Global Rights to Market

Micro PRO II-80

Rapid Micro Biosystems Enters Into Partnership with Life

Technologies II-80

 

9. FOCUS ON SELECT GLOBAL PLAYERS II-81

Abbott Laboratories (USA) II-81

Abbott Diagnostics (US) II-81

Alere Inc. (US) II-82

Becton Dickinson and Company (US) II-82

bioMerieux SA (France) II-83

bioMerieux, Inc. (USA) II-83

Bio-Rad Laboratories, Inc (US) II-84

Cellabs Pty Ltd (Australia) II-84

Celsis International Plc. (UK) II-84

Coris BioConcept (Belgium) II-85

F. Hoffmann-La Roche Ltd. (Switzerland) II-85

Hologic Gen-Probe Incorporated (US) II-86

MedMira, Inc. (Canada) II-87

Meridian Biosciences, Inc. (US) II-87

Orasure Technologies, Inc. (US) II-87

Orion Diagnostica Oy (Finland) II-88

Quidel Corp. (US) II-88

Sekisui Diagnostics (Japan) II-89

Siemens Healthcare Diagnostics, Inc. (USA) II-89

Thermo Fisher Scientific, Inc. (US) II-90

Oxoid Limited (UK) II-90

 

10. GLOBAL MARKET PERSPECTIVE II-92

Table 22: World Recent Past, Current & Future Analysis for

Automated and Rapid Microbiological Tests by Geographic Region-

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),

Latin America and Rest of World Independently Analyzed with

Annual Sales Figures in US$ Thousand for Years 2013 through

2020 (includes corresponding Graph/Chart) II-92

 

Table 23: World Historic Review for Automated and Rapid

Microbiological Tests by Geographic Region - US, Canada,

Japan, Europe, Asia-Pacific (excluding Japan), Latin America

and Rest of World Independently Analyzed with Annual Sales

Figures in US$ Thousand for Years 2006 through 2012 (includes

corresponding Graph/Chart) II-93

 

Table 24: World 15-Year Perspective for Automated and Rapid

Microbiological Tests by Geographic Region - Percentage

Breakdown of Dollar Sales for US, Canada, Japan, Europe,

Asia-Pacific (excluding Japan), Latin America and Rest of

World for Years 2006, 2014 & 2020 (includes corresponding

Graph/Chart) II-94

 

Table 25: World Recent Past, Current & Future Analysis for

Automated and Rapid Microbiological Tests in Clinical

Applications by Geographic Region - US, Canada, Japan, Europe,

Asia-Pacific (excluding Japan), Latin America and Rest of

World Independently Analyzed with Annual Sales Figures in US$

Thousand for Years 2013 through 2020 (includes corresponding

Graph/Chart) II-95

 

Table 26: World Historic Review for Automated and Rapid

Microbiological Tests in Clinical Applications by Geographic

Region - US, Canada, Japan, Europe, Asia-Pacific (excluding

Japan), Latin America and Rest of World Independently Analyzed

with Annual Sales Figures in US$ Thousand for Years 2006

through 2012 (includes corresponding Graph/Chart) II-96

 

Table 27: World 15-Year Perspective for Automated and Rapid

Microbiological Tests in Clinical Applications by Geographic

Region - Percentage Breakdown of Dollar Sales for US, Canada,

Japan, Europe, Asia-Pacific (excluding Japan), Latin America

and Rest of World for Years 2006, 2014 & 2020 (includes

corresponding Graph/Chart) II-97

 

Table 28: World Recent Past, Current & Future Analysis for

Automated and Rapid Microbiological Tests in Clinical

Applications by Segment - Automated Identification &

Susceptibility Systems, Automated Blood Culture Systems,

Automated Tuberculosis Systems, Streptococcal Infection Rapid

Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid

Microbiological Tests Independently Analyzed with Annual Sales

Figures in US$ Thousand for Years 2013 through 2020 (includes

corresponding Graph/Chart) II-98

 

Table 29: World Historic Review for Automated and Rapid

Microbiological Tests in Clinical Applications by Segment -

Automated Identification & Susceptibility Systems, Automated

Blood Culture Systems, Automated Tuberculosis Systems,

Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests,

and Other Automated & Rapid Microbiological Tests

Independently Analyzed with Annual Sales Figures in US$

Thousand for Years 2006 through 2012 (includes corresponding

Graph/Chart) II-99

 

Table 30: World 15-Year Perspective for Automated and Rapid

Microbiological Tests in Clinical Applications by Segment -

Percentage Breakdown of Dollar Sales for Automated

Identification & Susceptibility Systems, Automated Blood

Culture Systems, Automated Tuberculosis Systems, Streptococcal

Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other

Automated & Rapid Microbiological Tests for Years 2006, 2014 &

2020 (includes corresponding Graph/Chart) II-100

 

Table 31: World Recent Past, Current & Future Analysis for

Automated Identification & Susceptibility Systems in Clinical

Applications by Geographic Region - US, Canada, Japan, Europe,

Asia-Pacific (excluding Japan), Latin America and Rest of

World Independently Analyzed with Annual Sales Figures in US$

Thousand for Years 2013 through 2020 (includes corresponding

Graph/Chart) II-101

 

Table 32: World Historic Review for Automated Identification &

Susceptibility Systems in Clinical Applications by Geographic

Region - US, Canada, Japan, Europe, Asia-Pacific (excluding

Japan), Latin America and Rest of World Independently Analyzed

with Annual Sales Figures in US$ Thousand for Years 2006

through 2012 (includes corresponding Graph/Chart) II-102

 

Table 33: World 15-Year Perspective for Automated

Identification & Susceptibility Systems in Clinical

Applications by Geographic Region - Percentage Breakdown of

Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan), Latin America and Rest of World for Years

2006, 2014 & 2020 (includes corresponding Graph/Chart) II-103

 

Table 34: World Recent Past, Current & Future Analysis for

Automated Blood Culture Systems in Clinical Applications by

Geographic Region - US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan), Latin America and Rest of World

Independently Analyzed with Annual Sales Figures in US$

Thousand for Years 2013 through 2020 (includes corresponding

Graph/Chart) II-104

 

Table 35: World Historic Review for Automated Blood Culture

Systems in Clinical Applications by Geographic Region - US,

Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin

America and Rest of World Independently Analyzed with Annual

Sales Figures in US$ Thousand for Years 2006 through 2012

(includes corresponding Graph/Chart) II-105

 

Table 36: World 15-Year Perspective for Automated Blood

Culture Systems in Clinical Applications by Geographic Region

- Percentage Breakdown of Dollar Sales for US, Canada, Japan,

Europe, Asia-Pacific (excluding Japan), Latin America and Rest

of World for Years 2006, 2014 & 2020 (includes corresponding

Graph/Chart) II-106

 

Table 37: World Recent Past, Current & Future Analysis for

Automated Tuberculosis Systems in Clinical Applications by

Geographic Region - US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan), Latin America and Rest of World

Independently Analyzed with Annual Sales Figures in US$

Thousand for Years 2013 through 2020 (includes corresponding

Graph/Chart) II-107

 

Table 38: World Historic Review for Automated Tuberculosis

Systems in Clinical Applications by Geographic Region - US,

Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin

America and Rest of World Independently Analyzed with Annual

Sales Figures in US$ Thousand for Years 2006 through 2012

(includes corresponding Graph/Chart) II-108

 

Table 39: World 15-Year Perspective for Automated Tuberculosis

Systems in Clinical Applications by Geographic Region -

Percentage Breakdown of Dollar Sales for US, Canada, Japan,

Europe, Asia-Pacific (excluding Japan), Latin America and Rest

of World for Years 2006, 2014 & 2020 (includes corresponding

Graph/Chart) II-109

 

Table 40: World Recent Past, Current & Future Analysis for

Streptococcal Infection Rapid Tests in Clinical Applications

by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan), Latin America and Rest of World

Independently Analyzed with Annual Sales Figures in US$

Thousand for Years 2013 through 2020 (includes corresponding

Graph/Chart) II-110

 

Table 41: World Historic Review for Streptococcal Infection

Rapid Tests in Clinical Applications by Geographic Region -

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),

Latin America and Rest of World Independently Analyzed with

Annual Sales Figures in US$ Thousand for Years 2006 through

2012 (includes corresponding Graph/Chart) II-111

 

Table 42: World 15-Year Perspective for Streptococcal

Infection Rapid Testsin Clinical Applications by Geographic

Region - Percentage Breakdown of Dollar Sales for US, Canada,

Japan, Europe, Asia-Pacific (excluding Japan), Latin America

and Rest of World for Years 2006, 2014 & 2020 (includes

corresponding Graph/Chart) II-112

 

Table 43: World Recent Past, Current & Future Analysis for

GC/Chlamydia Rapid Tests in Clinical Applications by

Geographic Region - US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan), Latin America and Rest of World

Independently Analyzed with Annual Sales Figures in US$

Thousand for Years 2013 through 2020 (includes corresponding

Graph/Chart) II-113

 

Table 44: World Historic Review for GC/Chlamydia Rapid Tests

in Clinical Applications by Geographic Region - US, Canada,

Japan, Europe, Asia-Pacific (excluding Japan), Latin America

and Rest of World Independently Analyzed with Annual Sales

Figures in US$ Thousand for Years 2006 through 2012 (includes

corresponding Graph/Chart) II-114

 

Table 45: World 15-Year Perspective for GC/ Chlamydia Rapid

Tests in Clinical Applications by Geographic Region -

Percentage Breakdown of Dollar Sales for US, Canada, Japan,

Europe, Asia-Pacific (excluding Japan), Latin America and Rest

of World for Years 2006, 2014 & 2020 (includes corresponding

Graph/Chart) II-115

 

Table 46: World Recent Past, Current & Future Analysis for

Other Automated & Rapid Microbiological Tests in Clinical

Applications by Geographic Region - US, Canada, Japan, Europe,

Asia-Pacific (excluding Japan), Latin America and Rest of

World Independently Analyzed with Annual Sales Figures in US$

Thousand for Years 2013 through 2020 (includes corresponding

Graph/Chart) II-116

 

Table 47: World Historic Review for Other Automated & Rapid

Microbiological Tests in Clinical Applications by Geographic

Region - US, Canada, Japan, Europe, Asia-Pacific (excluding

Japan), Latin America and Rest of World Independently Analyzed

with Annual Sales Figures in US$ Thousand for Years 2006

through 2012 (includes corresponding Graph/Chart) II-117

 

Table 48: World 15-Year Perspective for Other Automated &

Rapid Microbiological Tests in Clinical Applications by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),

Latin America and Rest of World for Years 2006, 2014 & 2020

(includes corresponding Graph/Chart) II-118

 

Table 49: World Recent Past, Current & Future Analysis for

Automated and Rapid Microbiological Tests in Non-Clinical

Applications by Geographic Region - US, Canada, Japan, Europe,

Asia-Pacific (excluding Japan), Latin America and Rest of

World Independently Analyzed with Annual Sales Figures in US$

Thousand for Years 2013 through 2020 (includes corresponding

Graph/Chart) II-119

 

Table 50: World Historic Review for Automated and Rapid

Microbiological Tests in Non-Clinical Applications by

Geographic Region - US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan), Latin America and Rest of World

Independently Analyzed with Annual Sales Figures in US$

Thousand for Years 2006 through 2012 (includes corresponding

Graph/Chart) II-120

 

Table 51: World 15-Year Perspective for Automated and Rapid

Microbiological Tests in Non-Clinical Applications by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),

Latin America and Rest of World for Years 2006, 2014 & 2020

(includes corresponding Graph/Chart) II-121

 

 

III. MARKET

 

1. THE UNITED STATES III-1

A.Market Analysis III-1

Current & Future Analysis III-1

Changing Healthcare Industry Dynamics Affect Rapid and

Automated Microbiological Tests Market III-1

Table 52: Healthcare Spending as a % of GDP (includes

corresponding Graph/Chart) III-1

Positive Outlook for Rapid and Automated Microbiological

Tests Market III-2

Rapidly Ageing Demographics Drive Growth III-4

Table 53: North American Aging Population by Age Group:

1975-2050 (includes corresponding Graph/Chart) III-4

Competition III-5

Tracking Trends Across Product Segments III-5

Automated Identification & Susceptibility Systems III-5

Growing Popularity of FDA-Approved Automated

Susceptibility Testing Equipment III-5

STD Rapid Tests III-6

Market Shares of Leading Players III-6

Table 54: The US Market for Syphilis Rapid Tests by

Leading Player (2013) - Percentage Breakdown of Value

Sales for Alere, Becton Dickinson and Others (includes

corresponding Graph/Chart) III-6

HIV Rapid Testing Market III-7

Gastrointestinal Rapid Tests III-7

Table 55: The US Market for Rotavirus Rapid Tests by

Leading Player (2013) - Percentage Breakdown of Value

Sales for Meridian Biosciences, Thermo Fisher Scientific,

and Others (includes corresponding Graph/Chart) III-7

 

Table 56: The US Market for Giardia Rapid Tests by Leading

Player (2013) - Percentage Breakdown of Value Sales for

Becton Dickinson, Meridian Biosciences, and Oxoid

(includes corresponding Graph/Chart) III-7

Respiratory Rapid Tests III-8

Competition III-8

Market Share Data of Leading Players III-8

Table 57: The US Trichomonas Testing Market by Leading

Player (2013): Percentage Breakdown of Revenues for

Becton Dickinson and Co, and Hologic GenProbe Inc

(includes corresponding Graph/Chart) III-8

 

Table 58: The US Market for Influenza Rapid Tests by

Leading Player (2013) - Percentage Breakdown of Value

Sales for Becton Dickinson, Quidel, Thermo Fisher

Scientific and Others (includes corresponding

Graph/Chart) III-8

 

Table 59: The US Market for RSV Rapid Tests by Leading

Player (2013) - Percentage Breakdown of Value Sales for

Becton Dickinson, Binax, Thermo Fisher Scientific and

Others (includes corresponding Graph/Chart) III-9

 

Table 60: The US Market for Tuberculosis Rapid Tests by

Leading Player (2013) - Percentage Breakdown of Value

Sales for Becton Dickinson and Hologic Gen-Probe

(includes corresponding Graph/Chart) III-9

 

Table 61: The US Market for M. Pneumoniae Rapid Tests by

Leading Player (2013) - Percentage Breakdown of Value

Sales for Meridian Biosciences and Oxoid (includes

corresponding Graph/Chart) III-9

 

Table 62: The US Market for Mononucleosis Rapid Tests by

Leading Player (2013) - Percentage Breakdown of Value

Sales for Alere, Oxoid, Quidel and Others (includes

corresponding Graph/Chart) III-10

Streptococcus Infection Rapid Tests III-10

Table 63: The US Market for Streptococcus A Rapid Tests by

Leading Player (2013) - Percentage Breakdown of Value

Sales for Becton Dickinson, Quidel, Thermo Fisher

Scientific, and Others (includes corresponding

Graph/Chart) III-10

Testing Practices of the US Food Industry III-11

Table 64: US Food Safety Testing Market by Contaminant

(2013): Percentage Breakdown of Value Sales for Pathogens,

GMOs, Toxins, Residues and Others (includes corresponding

Graph/Chart) III-12

Increasing Demand for Microbiology Tests in the Food Sector III-12

Table 65: US Microbiological Food Safety Tests by Type

(2013): Percentage Share Breakdown in terms of Number of

Tests for Routine Tests and Pathogen Tests (includes

corresponding Graph/Chart) III-12

Tackling the Burden of Food Borne Illnesses III-13

Table 66: Food-borne Illnesses, Hospitalizations and Deaths

in the US (2012): Percentage Share Breakdown for Known

Pathogens and Unspecified Agents (includes corresponding

Graph/Chart) III-13

 

Table 67: Leading Pathogens Causing Food- borne Illnesses

in the US (2012): Percentage Share Breakdown of Number of

Illnesses by Known Pathogens - Norovirus, Salmonella

nontyphoidal, Clostridium perfringens, Campylobacter spp.,

Staphylococcus aureus, and Others (includes corresponding

Graph/Chart) III-14

 

Table 68: Leading Food-borne Pathogens Causing

Hospitalizations in the US (2012): Percentage Share

Breakdown of Number of Hospitalizations by Known Pathogens-

Salmonella nontyphoidal, Norovirus, Campylobacter spp.,

Toxoplasma gondii, E. coli (STEC) O157, and Others

(includes corresponding Graph/Chart) III-14

 

Table 69: Leading Food-borne Pathogens Causing Deaths in

the US (2012): Percentage Share Breakdown of Number of

Deaths by Known Pathogens - Salmonella nontyphoidal,

Norovirus, Campylobacter spp., Toxoplasma gondii, E. coli

(STEC) O157, and Others (includes corresponding

Graph/Chart) III-14

Product Launches III-15

Strategic Corporate Developments III-16

Select Key Players III-21

B.Market Analytics III-28

Table 70: The US Recent Past, Current & Future Analysis for

Automated & Rapid Microbiological Tests by End-Use

Application - Clinical Applications (Automated

Identification & Susceptibility Systems, Automated Blood

Culture Systems, Automated Tuberculosis Systems,

Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid

Tests, and Other Automated & Rapid Microbiological Tests)

and Non-Clinical Applications Independently Analyzed with

Annual Sales Figures in US$ Thousand for Years 2013 through

2020 (includes corresponding Graph/Chart) III-28

 

Table 71: The US Historic Review for Automated & Rapid

Microbiological Tests by End-Use Application - Clinical

Applications (Automated Identification& Susceptibility

Systems, Automated Blood Culture Systems, Automated

Tuberculosis Systems, Streptococcal Infection Rapid Tests,

GC/Chlamydia Rapid Tests, and Other Automated & Rapid

Microbiological Tests) and Non-Clinical Applications

Independently Analyzed with Annual Sales Figures in US$

Thousand for Years 2006 through 2012 (includes corresponding

Graph/Chart) III-29

 

Table 72: The US 15-Year Perspective for Automated & Rapid

Microbiological Tests by End-Use Application - Percentage

Breakdown of Dollar Sales for Clinical Applications

(Automated Identification & Susceptibility Systems,

Automated Blood Culture Systems, Automated Tuberculosis

Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia

Rapid Tests, and Other Automated & Rapid Microbiological

Tests) and Non-Clinical Applications for Years 2006, 2014 &

2020 (includes corresponding Graph/Chart) III-30

 

2. CANADA III-31

A.Market Analysis III-31

Current & Future Analysis III-31

Food Safety Testing in Canada III-31

Table 73: Canadian Food-Borne Illnesses by Category (2012):

Percentage Share Breakdown of Number of Illness Caused

through Known Pathogens and Unknown Pathogens (includes

corresponding Graph/Chart) III-32

 

Table 74: Canadian Food-Borne Illnesses by Pathogen (2012):

Percentage Breakdown of number of Illness Caused by

Norovirus, Clostridium perfringers, Campylobacter spp,

Salmonella spp., non-typhoidal and Others (includes

corresponding Graph/Chart) III-32

Strategic Corporate Developments III-33

MedMira, Inc. - A Key Player III-35

B.Market Analytics III-36

Table 75: Canadian Recent Past, Current & Future Analysis

for Automated & Rapid Microbiological Tests by End-Use

Segment - Clinical Applications (Automated Identification &

Susceptibility Systems, Automated Blood Culture Systems,

Automated Tuberculosis Systems, Streptococcal Infection

Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated &

Rapid Microbiological Tests) and Non-Clinical Applications

Independently Analyzed with Annual Sales Figures in US$

Thousand for Years 2013 through 2020 (includes corresponding

Graph/Chart) III-36

 

Table 76: Canadian Historic Review for Automated & Rapid

Microbiological Tests by End-Use Segment - Clinical

Applications (Automated Identification& Susceptibility

Systems, Automated Blood Culture Systems, Automated

Tuberculosis Systems, Streptococcal Infection Rapid Tests,

GC/Chlamydia Rapid Tests, and Other Automated & Rapid

Microbiological Tests) and Non-Clinical Applications

Independently Analyzed with Annual Sales Figures in US$

Thousand for Years 2006 through 2012 (includes corresponding

Graph/Chart) III-37

 

Table 77: Canadian 15-Year Perspective for Automated & Rapid

Microbiological Tests by End-Use Segment - Percentage

Breakdown of Dollar Sales for Clinical Applications

(Automated Identification & Susceptibility Systems,

Automated Blood Culture Systems, Automated Tuberculosis

Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia

Rapid Tests, and Other Automated & Rapid Microbiological

Tests) and Non-Clinical Applications for Years 2006, 2014 &

2020 (includes corresponding Graph/Chart) III-38

 

3. JAPAN III-39

A.Market Analysis III-39

Current & Future Analysis III-39

Demographics Drive Market Growth III-39

Table 78: Japanese Population by Age Group (2012) (includes

corresponding Graph/Chart) III-39

 

Table 79: Japanese 65+ Years Population: 1950-2010

(includes corresponding Graph/Chart) III-40

Strategic Corporate Development III-40

Sekisui Diagnostics - A Key Player III-40

B.Market Analytics III-42

Table 80: Japanese Recent Past, Current & Future Analysis

for Automated & Rapid Microbiological Tests by End-Use

Segment - Clinical Applications (Automated Identification &

Susceptibility Systems, Automated Blood Culture Systems,

Automated Tuberculosis Systems, Streptococcal Infection

Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated &

Rapid Microbiological Tests) and Non-Clinical Applications

Independently Analyzed with Annual Sales Figures in US$

Thousand for Years 2013 through 2020 (includes corresponding

Graph/Chart) III-42

 

Table 81: Japanese Historic Review for Automated & Rapid

Microbiological Tests by End-Use Segment - Clinical

Applications (Automated Identification& Susceptibility

Systems, Automated Blood Culture Systems, Automated

Tuberculosis Systems, Streptococcal Infection Rapid Tests,

GC/Chlamydia Rapid Tests, and Other Automated & Rapid

Microbiological Tests) and Non-Clinical Applications

Independently Analyzed with Annual Sales Figures in US$

Thousand for Years 2006 through 2012 (includes corresponding

Graph/Chart) III-43

 

Table 82: Japanese 15-Year Perspective for Automated & Rapid

Microbiological Tests by End-Use Segment - Percentage

Breakdown of Dollar Sales for Clinical Applications

(Automated Identification & Susceptibility Systems,

Automated Blood Culture Systems, Automated Tuberculosis

Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia

Rapid Tests, and Other Automated & Rapid Microbiological

Tests) and Non-Clinical Applications for Years 2006, 2014 &

2020 (includes corresponding Graph/Chart) III-44

 

4. EUROPE III-45

A.Market Analysis III-45

Current & Future Analysis III-45

Debt Crisis in Europe Affects Healthcare Industry III-45

European Healthcare System: In a State of Transition? III-45

Ageing Demography - An Opportunity Indicator III-46

Table 83: Population Breakup by Age Group for Select

European Countries: 2011 (as a Percentage of Total

Population) (includes corresponding Graph/Chart) III-47

Clinical Vis-à-vis Non-clinical Applications III-48

What Drives the Requirement Patterns of End-Users? III-48

Proliferation of Automated, and Rapid Tests in Clinical

Applications III-48

Non-clinical Applications III-49

Table 84: European Microbiological Food Safety Tests

(2012): Percentage Share Breakdown of Number of Tests by

Segment - Routine Tests and Pathogen Tests (includes

corresponding Graph/Chart) III-49

B.Market Analytics III-50

Table 85: European Recent Past, Current & Future Analysis

for Automated & Rapid Microbiological Tests by Geographic

Region - France, Germany, Italy, UK, Spain, Russia, & Rest

of Europe Independently Analyzed with Annual Sales Figures

in US$ Thousand for Years 2013 through 2020 (includes

corresponding Graph/Chart) III-50

 

Table 86: European Historic Review for Automated & Rapid

Microbiological Tests by Geographic Region - France,

Germany, Italy, UK, Spain, Russia, & Rest of Europe

Independently Analyzed with Annual Sales Figures in US$

Thousand for Years 2006 through 2012 (includes corresponding

Graph/Chart) III-51

 

Table 87: European 15-Year Perspective for Automated & Rapid

Microbiological Tests by Geographic Region - Percentage

Breakdown of Dollar Sales for France, Germany, Italy, UK,

Spain, Russia, & Rest of Europe for Years 2006, 2014 & 2020

(includes corresponding Graph/Chart) III-52

 

Table 88: European Recent Past, Current & Future Analysis

for Automated & Rapid Microbiological Tests by End-Use

Application - Clinical Applications (Automated

Identification & Susceptibility Systems, Automated Blood

Culture Systems, Automated Tuberculosis Systems,

Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid

Tests, and Other Automated & Rapid Microbiological Tests)

and Non-Clinical Applications Independently Analyzed with

Annual Sales Figures in US$ Thousand for Years 2013 through

2020 (includes corresponding Graph/Chart) III-53

 

Table 89: European Historic Review for Automated & Rapid

Microbiological Tests by End-Use Application- Clinical

Applications (Automated Identification & Susceptibility

Systems, Automated Blood Culture Systems, Automated

Tuberculosis Systems, Streptococcal Infection Rapid Tests,

GC/Chlamydia Rapid Tests, and Other Automated & Rapid

Microbiological Tests) and Non-Clinical Applications

Independently Analyzed with Annual Sales Figures in US$

Thousand for Years 2006 through 2012 (includes corresponding

Graph/Chart) III-54

 

Table 90: European 15-Year Perspective for Automated & Rapid

Microbiological Tests by End-Use Application - Percentage

Breakdown of Dollar Sales for Clinical Applications

(Automated Identification & Susceptibility Systems,

Automated Blood Culture Systems, Automated Tuberculosis

Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia

Rapid Tests, and Other Automated & Rapid Microbiological

Tests) and Non-Clinical Applications for Years 2006, 2014 &

2020 (includes corresponding Graph/Chart) III-55

 

4a. FRANCE III-56

A.Market Analysis III-56

Current & Future Analysis III-56

Product Launch III-56

Strategic Corporate Development III-57

bioMerieux SA - A Key Player III-57

B.Market Analytics III-58

Table 91: French Recent Past, Current & Future Analysis for

Automated & Rapid Microbiological Tests by End-Use

Application - Clinical Applications (Automated

Identification & Susceptibility Systems, Automated Blood

Culture Systems, Automated Tuberculosis Systems,

Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid

Tests, and Other Automated & Rapid Microbiological Tests)

and Non-Clinical Applications Independently Analyzed with

Annual Sales Figures in US$ Thousand for Years 2013 through

2020 (includes corresponding Graph/Chart) III-58

 

Table 92: French Historic Review for Automated & Rapid

Microbiological Tests by End-Use Application - Clinical

Applications (Automated Identification & Susceptibility

Systems, Automated Blood Culture Systems, Automated

Tuberculosis Systems, Streptococcal Infection Rapid Tests,

GC/ Chlamydia Rapid Tests, and Other Automated & Rapid

Microbiological Tests) and Non-Clinical Applications

Independently Analyzed with Annual Sales Figures in US$

Thousand for Years 2006 through 2012 (includes corresponding

Graph/Chart) III-59

 

Table 93: French 15-Year Perspective for Automated & Rapid

Microbiological Tests by End-Use Application - Percentage

Breakdown of Dollar Sales for Clinical Applications

(Automated Identification & Susceptibility Systems,

Automated Blood Culture Systems, Automated Tuberculosis

Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia

Rapid Tests, and Other Automated & Rapid Microbiological

Tests) and Non-Clinical Applications for Years 2006, 2014 &

2020 (includes corresponding Graph/Chart) III-60

 

4b. GERMANY III-61

A.Market Analysis III-61

Current & Future Analysis III-61

Food Safety - A Cause of Concern III-61

Food Safety Regulations in Germany III-61

Strategic Corporate Developments III-62

B.Market Analytics III-63

Table 94: German Recent Past, Current & Future Analysis for

Automated & Rapid Microbiological Tests by End-Use

Application - Clinical Applications (Automated

Identification & Susceptibility Systems, Automated Blood

Culture Systems, Automated Tuberculosis Systems,

Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid

Tests, and Other Automated & Rapid Microbiological Tests)

and Non-Clinical Applications Independently Analyzed with

Annual Sales Figures in US$ Thousand for Years 2013 through

2020 (includes corresponding Graph/Chart) III-63

 

Table 95: German Historic Review for Automated & Rapid

Microbiological Tests by End-Use Application - Clinical

Applications (Automated Identification & Susceptibility

Systems, Automated Blood Culture Systems, Automated

Tuberculosis Systems, Streptococcal Infection Rapid Tests,

GC/Chlamydia Rapid Tests, and Other Automated & Rapid

Microbiological Tests) and Non-Clinical Applications

Independently Analyzed with Annual Sales Figures in US$

Thousand for Years 2006 through 2012 (includes corresponding

Graph/Chart) III-64

 

Table 96: German 15-Year Perspective for Automated & Rapid

Microbiological Tests by End-Use Application - Percentage

Breakdown of Dollar Sales for Clinical Applications

(Automated Identification & Susceptibility Systems,

Automated Blood Culture Systems, Automated Tuberculosis

Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia

Rapid Tests, and Other Automated & Rapid Microbiological

Tests) and Non-Clinical Applications for Years 2006, 2014 &

2020 (includes corresponding Graph/Chart) III-65

 

4c. ITALY III-66

A.Market Analysis III-66

Current & Future Analysis III-66

B.Market Analytics III-67

Table 97: Italian Recent Past, Current & Future Analysis for

Automated & Rapid Microbiological Tests by End-Use

Application - Clinical Applications (Automated

Identification & Susceptibility Systems, Automated Blood

Culture Systems, Automated Tuberculosis Systems,

Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid

Tests, and Other Automated & Rapid Microbiological Tests)<

 

 

To order this report: Global Automated And Rapid Microbiological Tests Market

http://www.reportlinker.com/p092467/Global-Automated-And-Rapid-Microbiological-Tests-Market.html

__________________________

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

10 Orms Street Providence, R.I. 02904
401-453-8000

All content © Copyright 2000 - 2014 WorldNow and WLNE.
All Rights Reserved.

For more information on this site, please read our Privacy Policy and Terms of Service.